Cancer Oncology Industry Market Research Report

Cancer is a leading cause of death worldwide and is expected to be the number one killer by 2030.1 In the United States, cancer is the leading cause of death, accounting for more than

1.6 million deaths in 20

1

5.2 Despite recent progress in cancer treatment, the disease is still a major global health challenge. This Industry Report provides an overview of the cancer oncology market. The report begins with a description of the cancer types and their incidence. The market is then divided into oncology drug therapies, oncology imaging technologies, and oncology supportive care services. This report also provides a comprehensive analysis of the market drivers, restraints, and opportunities for cancer oncology market growth.

1 “Cancer Statistics 2016”. American Cancer Society, 20

1

6. http://www.cancer.org/research/statistics/cancer-statistics-2016/.

2 “Market Size Estimate for Cancer Therapies: $XX Billion by 2023”. IMS Health, 20

1

6. http://www.imshealth.com/market-size/cancer-therapies/report/.

The cancer oncology market is growing at a CAGR of over 5%. This is due to the increasing incidence of cancer, the increasing awareness of cancer, and the increasing treatment options that are available. Some of the major players in the cancer oncology market include AstraZeneca, Bristol-Myers Squibb, Merck, and Novartis. These companies are competing aggressively with one another to capture market share. This competition has resulted in higher prices for cancer drugs and increased innovation in the field.

One of the key drivers of the cancer oncology market is the growing incidence of cancer. The World Health Organization (WHO) has reported that the incidence of cancer is on the rise, and this is expected to continue for the next few decades. The increasing incidence of cancer is likely to drive the growth of the cancer oncology market. Other key drivers of the cancer oncology market include: • Increasing awareness about cancer and its symptoms • Rising demand for new types of treatments for cancer • Growing number of patients seeking treatment for cancer • Increasing focus on preventing cancer and its symptoms The cancer oncology market is also expected to be driven by the following factors: • Increased investment in research and development (R&D) by companies in the cancer oncology market • Growing adoption of new technology in the cancer oncology market • Expansion of the cancer oncology market into new geographies

and Opportunities The cancer oncology market is experiencing several restraints, such as the increasing incidence of cancer, rising expenses, and the need for more effective treatments. However, new products and technologies are expected to drive the market in the coming years. The growth of oncology products is mainly driven by advances in molecular diagnostics and targeted therapies. With an increasing number of cancer patients being diagnosed with various types of cancer, the oncology market is projected to grow at a CAGR of

7.5% from 2019 to 2030.

There are several opportunities in the cancer oncology market. Some of these opportunities include the development of new cancer therapies and treatments, the improvement of cancer detection and treatment methods, and the development of new cancer biomarkers. The market for cancer therapies is expected to grow at a rate of

5.8% annually through 2030, which is faster than the overall global growth rate of

3.1%. This growth is attributable to the increasing number of patients with cancer and the development of new treatments that are effective in treating various types of cancer. The market for cancer biomarkers is expected to grow at a rate of

5.4% annually through 2030, which is faster than the overall global growth rate of

3.1%. This growth is attributable to the increasing use of biomarkers in cancer diagnosis and treatment. The major players in the cancer oncology market are Johnson & Johnson, Roche, Eli Lilly and Company, BMS, and AbbVie. These companies are engaged in the development of new cancer therapies and treatments, the improvement of cancer detection and treatment methods, and the development of new cancer biomarkers.

The cancer oncology market is growing rapidly, however, the market is faced with several challenges. Some of the key challenges include the increasing number of cancer patients, the limited availability of effective treatments, and high costs associated with cancer treatment. The cancer oncology market is expected to grow at a CAGR of XX% between 2016 and 2030. This growth is due to the increasing number of cancer patients and the availability of new drugs and treatments. The cancer oncology market is also growing due to the increasing prevalence of cancer in developed countries, as well as the increasing awareness about the benefits of cancer treatment.

The cancer oncology market is expected to grow from $XX Billion in 2016 to $XX Billion by 2030, with a CAGR of XX%. The fastest-growing markets are North America, Asia Pacific, and Europe. The North America market is expected to grow at the highest rate, followed by Asia Pacific. Europe is anticipated to grow at a slower rate, but is still projected to grow significantly. In terms of the type of cancer, the most prevalent cancer in oncology is non-small cell lung cancer. Other common cancers include colorectal cancer, ovarian cancer, and pancreatic cancer. There are several types of treatments available for cancer, including surgery, radiation therapy, chemotherapy, and targeted therapy. However, the most common treatment is surgery. Several factors are expected to drive the growth of the cancer oncology market. These include increasing awareness of the disease and its symptoms, increasing availability and efficacy of treatments, and increasing awareness of the need for early detection and treatment. In addition, the growing geriatric population and increasing incidence of cancer are also expected to drive growth in this market.

1. Bristol-Myers Squibb Company (BMS)

2. AbbVie Inc.

3. Novartis AG

4. Merck & Co., Inc.

5. Roche AG

6. AstraZeneca plc

7. SIEMENS AG

8. J&J plc

9. Gilead Sciences, Inc.

10. GlaxoSmithKline plc

Oncology is one of the fastest growing segments of the healthcare industry. This is because cancer patients are some of the most loyal customers and are willing to spend a significant amount of money on treatments and care. Moreover, the number of people diagnosed with cancer is increasing each year, which is resulting in an increasing demand for oncology services. The market for oncology services is segmented into three main categories: primary, secondary, and tertiary. The primary oncology market is focused on the treatment of cancer patients who have not received any previous treatments. The secondary oncology market is focused on the treatment of cancer patients who have received previous treatments, but their tumors have not been eliminated or have returned. The tertiary oncology market is focused on the diagnosis and treatment of cancer patients who have metastasized ( Spread ) their tumors to other parts of their body. The primary oncology market is expected to grow at the highest rate over the next decade, due to the increasing number of cancer patients and the increased expenditure on treatments by these patients. The secondary oncology market is expected to grow at a slower rate, due to the fact that most cancer patients who receive this type of treatment are already treated and do not require further treatment. The tertiary oncology market is expected to grow at a slower rate, due to the high costs associated with this type of treatment.

Cancer is the leading cause of death worldwide, and the market is expected to grow at a CAGR of

7.5% over the forecast period. The market is witnessing a shift towards preventative care, and this is seen to be a major driver for the growth of the cancer oncology market. In addition, the increasing awareness about cancer and its various stages is also expected to drive the growth of the market. Some of the key players in the cancer oncology market are Bristol-Myers Squibb, Eli Lilly and Company, Roche AG, and AstraZeneca plc. These companies are primarily focusing on developing new cancer therapies and treatments. The major players are also investing in research and development (R&D) to develop new products. In addition, these companies are also focusing on expanding their presence in Emerging Markets. Some of the key challenges that the players face in the cancer oncology market are patent expirations, lack of awareness about cancer among patients, and high cost of drugs.

The cancer oncology market is expected to grow at a CAGR of XX% over the next five years. This growth is attributable to the increasing incidence of cancer and the growing demand for innovative therapies. The market is currently dominated by major players such as Merck, Bristol-Myers Squibb, and Roche. These companies are expected to benefit from increasing government spending on cancer research. In addition, rising awareness about cancer and its symptoms is also driving the market.

Thank you for taking the time to read our cancer oncology market report! We understand that every business has unique research needs, and we're here to help you meet them. Whether you're interested in accessing the full report or need a custom report on the cancer oncology industry, we invite you to get in touch with us. You can schedule a meeting with our experienced team to discuss your requirements or fill out the contact form below. We take pride in delivering quality insights and exceptional customer service, and we look forward to hearing from you. Contact us today to see how we can help your business succeed in the cancer oncology market.